Loading…
World's largest dental-implant maker, also selling clear aligners (ClearCorrect) and dental imaging/CAD-CAM equipment.
World's largest dental-implant maker, also selling clear aligners (ClearCorrect) and dental imaging/CAD-CAM equipment.
Sells implants and the abutments and crowns that go with them to dentists, who tend to stay with the system they were trained on, so a clinic's choice repeats with each patient; premium implants carry the margin, while Neodent in Brazil and Anthogyr in France serve value segments. Clear aligners came with ClearCorrect, bought in 2017.
In one line: The implant+aligner leader, like a combined Align Technology and Dentsply implants unit.
Moat: narrow (brand, switching costs, distribution). Implant systems need dentist training/certification, creating switching costs once a clinic standardizes.
Headquarters: Basel, Switzerland · Founded: 1954 · Employees: 11,824
Size Straumann (STMN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $20.4B, the 26th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 104.50 on 6 Nov 2026.
Performance Over six months the shares gained 25.1%, against +29.8% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +7.7%); the operating margin is 21.1% (peer median 17.4%).
Valuation It trades at 31.9× forward earnings against a peer median of 27.0× (9th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.4 points above its cost of capital (7.0% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 2.64B | CHF 2.61B | CHF 2.50B | CHF 2.28B | CHF 2.32B |
| Revenue growth | — | +4% | +10% | -2% | — |
| Gross profit | CHF 1.79B | CHF 1.77B | CHF 1.77B | CHF 1.68B | CHF 1.70B |
| EBITDA | CHF 716M | CHF 696M | CHF 731M | CHF 715M | CHF 693M |
| Net income | CHF 369M | CHF 356M | CHF 387M | CHF 246M | CHF 435M |
| Free cash flow | CHF 383M | CHF 330M | CHF 366M | CHF 354M | CHF 255M |
| Capital expenditure | CHF 185M | CHF 223M | CHF 168M | CHF 187M | CHF 195M |
| Total debt | n/a | CHF 503M | CHF 465M | CHF 445M | CHF 705M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Straumann STMN.SW | $20.4B | +25% | +2% | 21% | 31.9× | 15.2% |
| DENTSPLY SIRONA XRAY | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% |
| Align Technology ALGN | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% |
| Envista NVST | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% |
| Zimmer Biomet ZBH | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STMN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.0% | +9.3% | 4th highest of 21 |
| 6-month return | +25.1% | +29.8% | 8th lowest of 21 |
| Distance from 52-week high | -4.8% | -12.0% | 4th highest of 21 |
| Revenue growth (TTM) | +2.2% | +7.7% | 3rd lowest of 21 |
| Operating margin | 21.1% | 17.4% | 6th highest of 21 |
| Forward P/E | 31.9× | 27.0× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 15.2% | 13.7% | 9th most demanding of 18 |
| Growth delivered (Del g) | +12.8% | +8.7% | 6th highest of 18 |
| Hurdle (Req g minus delivered) | +2.4 pp | +5.5 pp | 9th least demanding of 18 |
| ROIC minus cost of capital | +11.4 pp | +2.0 pp | 4th highest of 21 |
| EV / EBITDA | 23.5× | 18.5× | 6th most expensive of 17 |
| Net debt / EBITDA | 0.2× | 1.0× | 5th least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Straumann STMN.SW | Switzerland | $20.4B | +25% | +2% | 21% | 31.9× | 15.2% | +12.8% |
| Sonova SOON.SW | Switzerland | $20.3B | +62% | -7% | 21% | 25.6× | 7.1% | +6.7% |
| Guardant Health GH | United States | $20.2B | +58% | +43% | -40% | n/a | n/a | n/a |
| Zimmer Biomet ZBH | United States | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% | +3.2% |
| Sartorius SRT.DE | Germany | $20.0B | +34% | +4% | 18% | 42.6× | 24.9% | +8.7% |
| Terumo 4543.T | Japan | $23.4B | +25% | +14% | 17% | 24.6× | 8.7% | +13.0% |
| Coloplast A/S COLO-B.CO | Denmark | $17.7B | +26% | +4% | 25% | 19.9× | -1.8% | +8.3% |
| Revvity RVTY | United States | $17.3B | +54% | +5% | 15% | 26.7× | 27.3% | -5.5% |
| Steris STE | United States | $24.6B | +22% | +8% | 20% | 21.4× | 13.7% | +13.8% |
| Sartorius Stedim Biotech DIM.PA | France | $24.7B | +38% | +4% | 19% | 45.5× | 33.1% | +9.2% |
| West Pharmaceutical Services WST | United States | $27.9B | +23% | +13% | 23% | 39.8× | 25.2% | +7.5% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 46.9× | n/a | n/a |
| Dexcom DXCM | United States | $29.6B | +31% | +13% | 24% | 27.0× | 18.5% | +19.3% |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Illumina ILMN | United States | $32.2B | +50% | +6% | 21% | 35.7× | 27.1% | +6.0% |
| ResMed RMD | United States | $33.1B | +14% | +9% | 34% | 19.1× | 4.9% | +12.1% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.4B | +9% | +5% | 28% | 27.1× | 0.9% | +9.7% |